Skip to main content
SpringerLink
Log in

Patient’s Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms

  • Chapter
  • First Online:
Myeloproliferative Neoplasms

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 995 Accesses

Abstract

Informing a patient diagnosed with a myeloproliferative neoplasm (MPN) is an important clinical task for the treating physician. Information should include aspects such as the patient’s awareness of the neoplastic nature of the disease, simple notions on its molecular basis (primarily, the current knowledge on the significance of the presence of the JAK2 mutation), recognition of symptoms that can be derived from the disease, possible complications, the importance of a strict control of cardiovascular risk factors (including smoking cessation), life expectancy, prognostic stratification, currently available therapeutic options, and new drugs under investigation. MPN patients should know that in these diseases, treatment is mostly driven by the clinical findings or the risk of developing certain complications, such as thrombosis and bleeding. Despite the neoplastic nature of the MPNs, it is advisable to distinguish these disorders from leukemia, with this especially applying to polycythemia vera (PV) or essential thrombocythemia (ET), associated with a life expectancy not substantially different from that of the general population. Beside, other practical aspects, such as how to proceed in pregnancy or surgery could also be discussed whenever applicable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770

    Article  PubMed  Google Scholar 

  • Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113:4829–4833

    Article  PubMed  CAS  Google Scholar 

  • Buss DH, Stuart JJ, Lipscomb GE (1985) The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 20:365–372

    Article  PubMed  CAS  Google Scholar 

  • Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355:2452–2466

    Article  PubMed  CAS  Google Scholar 

  • Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, Wheatley K, Harrison CN, Green AR (2009) Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 27:2991–2999

    Article  PubMed  CAS  Google Scholar 

  • Cervantes F, Pereira A, Esteve J, Rafel M, Cobo F, Rozman C, Montserrat E (1997) Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635–640

    Article  PubMed  CAS  Google Scholar 

  • Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895–2901

    Article  PubMed  CAS  Google Scholar 

  • Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132–1136

    Article  PubMed  CAS  Google Scholar 

  • Diez-Martin JL, Graham DL, Petitt RM, Dewald GW (1991) Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 66:287–299

    PubMed  CAS  Google Scholar 

  • Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105:2664–2670

    Article  PubMed  CAS  Google Scholar 

  • Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR (1997) From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34:17–23

    PubMed  CAS  Google Scholar 

  • Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A (2006) Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer 106:2406–2411

    Article  PubMed  CAS  Google Scholar 

  • Gangat N, Tefferi A, Thanarajasingam G, Patnaik M, Schwager S, Ketterling R, Wolanskyj AP (2009) Cyto­genetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol 83:17–21

    Article  PubMed  CAS  Google Scholar 

  • Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392–397

    Article  PubMed  Google Scholar 

  • Harrison C (2005) Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 129:293–306

    Article  PubMed  CAS  Google Scholar 

  • Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45

    Article  PubMed  CAS  Google Scholar 

  • Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, Erber W, Everington T, Green AR, Hall GW, Hunt BJ, Ludlam CA, Murrin R, Nelson-Piercy C, Radia DH, Reilly JT, Van der Walt J, Wilkins B, McMullin MF (2010) Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 149:352–375

    Article  PubMed  CAS  Google Scholar 

  • Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A (2010) International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 115:496–499

    Article  PubMed  CAS  Google Scholar 

  • Johansson P, Kutti J, Andreasson B, Safai-Kutti S, Vilen L, Wedel H, Ridell B (2004) Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983–99. J Intern Med 256:161–165

    Article  PubMed  CAS  Google Scholar 

  • Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Collins A, Reiter A, Grand F, Cross NC (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446–449

    Article  PubMed  CAS  Google Scholar 

  • Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P (2006) Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 32:417–421

    Article  PubMed  CAS  Google Scholar 

  • Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114:5264–5270

    Article  PubMed  Google Scholar 

  • Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M (2008) Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 112:2199–2204

    Article  PubMed  CAS  Google Scholar 

  • Landolfi R, Di Gennaro L, Falanga A (2008) Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 22:2020–2028

    Article  PubMed  CAS  Google Scholar 

  • Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29–39

    PubMed  CAS  Google Scholar 

  • Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755–761

    Article  PubMed  Google Scholar 

  • Passamonti F, Randi ML, Rumi E, Pungolino E, Elena C, Pietra D, Scapin M, Arcaini L, Tezza F, Moratti R, Pascutto C, Fabris F, Morra E, Cazzola M, Lazzarino M (2007) Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 110:485–489

    Article  PubMed  CAS  Google Scholar 

  • Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT (1991) Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658–2663

    Article  PubMed  CAS  Google Scholar 

  • Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F (2002) Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 71:1–6

    Article  PubMed  CAS  Google Scholar 

  • Ruggeri M, Rodeghiero F, Tosetto A, Castaman G, Scognamiglio F, Finazzi G, Delaini F, Mico C, Vannucchi AM, Antonioli E, De Stefano V, Za T, Gugliotta L, Tieghi A, Mazzucconi MG, Santoro C, Barbui T (2008) Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111:666–671

    Article  PubMed  CAS  Google Scholar 

  • Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L, Del Curto C, Pietra D, Boveri E, Pascutto C, Cazzola M, Lazzarino M (2007) Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 25:5630–5635

    Article  PubMed  Google Scholar 

  • Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S (2009) The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 113:4171–4178

    Article  PubMed  CAS  Google Scholar 

  • Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172–176

    PubMed  CAS  Google Scholar 

  • Tefferi A (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24:1128–1138

    Article  PubMed  CAS  Google Scholar 

  • Tefferi A, Fonseca R (2002) Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 99:2627

    Article  PubMed  CAS  Google Scholar 

  • Tefferi A, Vainchenker W (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 29:573–582

    Article  PubMed  CAS  Google Scholar 

  • Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95:2226–2233

    PubMed  CAS  Google Scholar 

  • Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H (2006) Inter­national Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108:1497–1503

    Article  PubMed  CAS  Google Scholar 

  • Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117–1127

    Article  PubMed  CAS  Google Scholar 

  • Willoughby S, Pearson TC (1998) The use of aspirin in polycythaemia vera and primary thrombocythaemia. Blood Rev 12:12–22

    Article  PubMed  CAS  Google Scholar 

  • Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81:159–166

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain

    Francisco Cervantes

  2. Hematology Department, Hospital Clínico, Valencia, Spain

    Juan-Carlos Hernández-Boluda

Authors
  1. Francisco Cervantes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juan-Carlos Hernández-Boluda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francisco Cervantes .

Editor information

Editors and Affiliations

  1. Div. Ematologia, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, 24128, Italy

    Tiziano Barbui

  2. Dept. Internal Medicine, Div. Hematology, Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    Ayalew Tefferi

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Cervantes, F., Hernández-Boluda, JC. (2012). Patient’s Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms. In: Barbui, T., Tefferi, A. (eds) Myeloproliferative Neoplasms. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-24989-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-24989-1_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-24988-4

  • Online ISBN: 978-3-642-24989-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation